Abstract
Aim:
To test whether pharmacological inhibition of Diacylglycerol acyltransferase 1 (DGAT1) by a small-molecule inhibitor H128 can improve metabolism disorders in leptin receptor-deficient db/db mice.
Methods:
To investigate the effect of H128 on intestinal fat absorption,db/db mice were acutely given a bolus of corn oil by gavage. The mice were further orally administered H128 (3 and 10 mg/kg) for 5 weeks. Blood glucose, lipids, insulin, ALT, and AST as well as hepatic triglycerides were measured. The insulin tolerance test was performed to evaluate insulin sensitivity. The expression of genes involved in fatty acid oxidation was detected by RT-PCR.
Results:
Oral administration of H128 (10 mg/kg) acutely inhibited intestinal fat absorption following a lipid challenge in db/db mice. Chronic treatment with H128 significantly inhibited body weight gain, decreased food intake, and induced a pronounced reduction of serum triglycerides. In addition, H128 treatment markedly ameliorated hepatic steatosis, characterized by decreased liver weight, lipid droplets, and triglyceride content as well as serum ALT and AST levels. Furthermore, H128 treatment increased the expression of the CPT1 and PPARĪ± genes in liver, suggesting that H128 enhanced fatty acid oxidation in db/db mice. However, neither blood glucose nor insulin tolerance was affected by H128 treatment throughout the 5-week experimental period.
Conclusion:
DGAT1 may be an effective therapeutic target for the treatment of obesity, hyperlipidemia and hepatic steatosis.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
LeRoith D . Dyslipidemia and glucose dysregulation in overweight and obese patients. Clin Cornerstone 2007; 8: 38ā52.
Bray GA, Bellanger T . Epidemiology, trends, and morbidities of obesity and the metabolic syndrome. Endocrine 2006; 29: 109ā17.
Heber D . An integrative view of obesity. Am J Clin Nutr 2010; 91: 280Sā83S.
Chen HC . Farese RV Jr . Inhibition of triglyceride synthesis as a treatment strategy for obesity: lessons from DGAT1-deficient mice. Arterioscler Thromb Vasc Biol 2005; 25: 482ā6.
Dickerson LM, Carek PJ . Pharmacotherapy for the obese patient. Prim Care 2009; 36: 407ā15.
Buhman KK, Chen HC, Farese RV Jr . The enzymes of neutral lipid synthesis. J Biol Chem 2001; 276: 40369ā72.
Cases S, Smith SJ, Zheng YW, Myers HM, Lear SR, Sande E, et al. Identification of a gene encoding an acyl CoA:diacylglycerol acyltransferase, a key enzyme in triacylglycerol synthesis. Proc Natl Acad Sci USA 1998; 95: 13018ā23.
Cases S, Stone SJ, Zhou P, Yen E, Tow B, Lardizabal KD, et al. Cloning of DGAT2, a second mammalian diacylglycerol acyltransferase, and related family members. J Biol Chem 2001; 276: 38870ā6.
Yen CL, Stone SJ, Koliwad S, Harris C, Farese RV Jr . Thematic review series: glycerolipids. DGAT enzymes and triacylglycerol biosynthesis. J Lipid Res 2008; 49: 2283ā301.
Stone SJ, Myers HM, Watkins SM, Brown BE, Feingold KR, Elias PM, et al. Lipopenia and skin barrier abnormalities in DGAT2-deficient mice. J Biol Chem 2004; 279: 11767ā76.
Chen HC, Ladha Z, Smith SJ, Farese RV Jr . Analysis of energy expenditure at different ambient temperatures in mice lacking DGAT1. Am J Physiol Endocrinol Metab 2003; 284: E213ā8.
Chen HC, Smith SJ, Ladha Z, Jensen DR, Ferreira LD, Pulawa LK, et al. Increased insulin and leptin sensitivity in mice lacking acyl CoA:diacylglycerol acyltransferase 1. J Clin Invest 2002; 109: 1049ā55.
Smith SJ, Cases S, Jensen DR, Chen HC, Sande E, Tow B, et al. Obesity resistance and multiple mechanisms of triglyceride synthesis in mice lacking Dgat. Nat Genet 2000; 25: 87ā90.
Chen HC, Rao M, Sajan MP, Standaert M, Kanoh Y, Miura A, et al. Role of adipocyte-derived factors in enhancing insulin signaling in skeletal muscle and white adipose tissue of mice lacking Acyl CoA:diacylglycerol acyltransferase 1. Diabetes 2004; 53: 1445ā51.
Villanueva CJ, Monetti M, Shih M, Zhou P, Watkins SM, Bhanot S, et al. Specific role for acyl CoA:Diacylglycerol acyltransferase 1 (Dgat1) in hepatic steatosis due to exogenous fatty acids. Hepatology 2009; 50: 434ā42.
Matsuda D, Tomoda H . DGAT inhibitors for obesity. Curr Opin Investig Drugs 2007; 8: 836ā41.
Chen HC . Farese RV Jr . DGAT and triglyceride synthesis: a new target for obesity treatment? Trends Cardiovasc Med 2000; 10: 188ā92.
Birch AM, Birtles S, Buckett LK, Kemmitt PD, Smith GJ, Smith TJ, et al. Discovery of a potent, selective, and orally efficacious pyrimidinooxazinyl bicyclooctaneacetic acid diacylglycerol acyltransferase-1 inhibitor. J Med Chem 2009; 52: 1558ā68.
Zhao G, Souers AJ, Voorbach M, Falls HD, Droz B, Brodjian S, et al. Validation of diacyl glycerolacyltransferase I as a novel target for the treatment of obesity and dyslipidemia using a potent and selective small molecule inhibitor. J Med Chem 2008; 51: 380ā3.
Cool B, Zinker B, Chiou W, Kifle L, Cao N, Perham M, et al. Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome. Cell Metab 2006; 3: 403ā16.
Goepfert S, Poirier Y . Beta-oxidation in fatty acid degradation and beyond. Curr Opin Plant Biol 2007; 10: 245ā51.
Nakamura MT, Nara TY . Essential fatty acid synthesis and its regulation in mammals. Prostaglandins Leukot Essent Fatty Acids 2003; 68: 145ā50.
Buhman KK, Smith SJ, Stone SJ, Repa JJ, Wong JS, Knapp FF Jr, et al. DGAT1 is not essential for intestinal triacylglycerol absorption or chylomicron synthesis. J Biol Chem 2002; 277: 25474ā9.
Cheng D, Iqbal J, Devenny J, Chu CH, Chen L, Dong J, et al. Acylation of acylglycerols by acyl coenzyme A:diacylglycerol acyltransferase 1 (DGAT1). Functional importance of DGAT1 in the intestinal fat absorption. J Biol Chem 2008; 283: 29802ā11.
Shi Y, Cheng D . Beyond triglyceride synthesis: the dynamic functional roles of MGAT and DGAT enzymes in energy metabolism. Am J Physiol Endocrinol Metab 2009; 297: E10ā8.
Thupari JN, Landree LE, Ronnett GV, Kuhajda FP . C75 increases peripheral energy utilization and fatty acid oxidation in diet-induced obesity. Proc Natl Acad Sci USA 2002; 99: 9498ā502.
Bebernitz GR, Schuster HF . The impact of fatty acid oxidation on energy utilization: targets and therapy. Curr Pharm Des 2002; 8: 1199ā227.
Minokoshi Y, Kim YB, Peroni OD, Fryer LG, Muller C, Carling D, et al. Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature 2002; 415: 339ā43.
Suzuki A, Okamoto S, Lee S, Saito K, Shiuchi T, Minokoshi Y . Leptin stimulates fatty acid oxidation and peroxisome proliferator-activated receptor alpha gene expression in mouse C2C12 myoblasts by changing the subcellular localization of the alpha2 form of AMP-activated protein kinase. Mol Cell Biol 2007; 27: 4317ā27.
Farese RV Jr, Cases S, Smith SJ . Triglyceride synthesis: insights from the cloning of diacylglycerol acyltransferase. Curr Opin Lipidol 2000; 11: 229ā34.
Kohjima M, Enjoji M, Higuchi N, Kato M, Kotoh K, Yoshimoto T, et al. Re-evaluation of fatty acid metabolism-related gene expression in nonalcoholic fatty liver disease. Int J Mol Med 2007; 20: 351ā8.
Marchesini G, Marzocchi R, Agostini F, Bugianesi E . Nonalcoholic fatty liver disease and the metabolic syndrome. Curr Opin Lipidol 2005; 16: 421ā7.
Petersen KF, Shulman GI . Etiology of insulin resistance. Am J Med 2006; 119: S10ā6.
Kelley DE, McKolanis TM, Hegazi RA, Kuller LH, Kalhan SC . Fatty liver in type 2 diabetes mellitus: relation to regional adiposity, fatty acids, and insulin resistance. Am J Physiol Endocrinol Metab 2003; 285: E906ā16.
Monetti M, Levin MC, Watt MJ, Sajan MP, Marmor S, Hubbard BK, et al. Dissociation of hepatic steatosis and insulin resistance in mice overexpressing DGAT in the liver. Cell Metab 2007; 6: 69ā78.
Shah S, Iqbal M, Karam J, Salifu M, McFarlane SI . Oxidative stress, glucose metabolism, and the prevention of type 2 diabetes: pathophysiological insights. Antioxid Redox Signal 2007; 9: 911ā29
Acknowledgements
This work was supported by Grant 2009ZX09301-001 from the National Science & Technology Major Project āKey New Drug Creation and Manufacturing Programā, by Grant 2007AA02Z301 from the National High Technology Research and Development Program of China (863 Program), by Grant 20972174 from the National Natural Science Foundation of China, by Grant 10410703900 from the Shanghai Committee of Science and Technology, by Grant 08431900800 from the Shanghai Science and Technology Innovation Program and by the Program for Professor of Special Appointment (Eastern Scholar) at Shanghai Institutions of Higher Learning.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Zhang, Xd., Yan, Jw., Yan, Gr. et al. Pharmacological inhibition of diacylglycerol acyltransferase 1 reduces body weight gain, hyperlipidemia, and hepatic steatosis in db/db mice. Acta Pharmacol Sin 31, 1470ā1477 (2010). https://doi.org/10.1038/aps.2010.104
Received:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/aps.2010.104
